Group 1 - Huawei's rotating chairman Meng Wanzhou emphasizes the importance of resilience and professionalism in overcoming challenges and creating value in the face of the intelligent transformation wave, highlighting the need for strategic focus and organizational strength by 2026 [27] - Hengrui Medicine plans to increase R&D investment, focusing on oncology, autoimmune, and metabolic diseases, aiming to address unmet clinical needs and enhance international cooperation for global commercialization of Chinese innovative drugs by 2026 [28] - Wanhua Chemical's chairman Liao Zengtai aims to enhance operational quality and focus on technological innovation, particularly in battery materials and high-end new materials, to create a competitive advantage and develop an integrated growth model by 2026 [29] Group 2 - Muyuan Foods' chairman Qin Yinglin reflects on the company's journey from starting with 22 pigs to becoming the largest pig farming enterprise globally, emphasizing the importance of innovation and technology in achieving a dignified and efficient pig farming process by 2026 [30] - Gree Electric's chairman Dong Mingzhu commits to deepening core business and accelerating in smart equipment and new energy sectors, while focusing on green and digital transformation to enhance product quality and service for global users by 2026 [31] - Geely Holding Group's chairman Li Shufu highlights the importance of making bold decisions during critical moments, emphasizing the need to overcome challenges and maintain core values as the company approaches its 40th anniversary in 2026 [32] Group 3 - SAIC Motor's chairman Wang Xiaoqiu outlines the company's commitment to deepening reforms and focusing on intelligent and electric vehicle development, aiming for high-quality growth and user-centered innovation by 2026 [32] - Hengli Group's chairman Chen Jianhua stresses the importance of practical action and innovation in overcoming development challenges, encouraging a proactive approach to seize opportunities in the coming years [33] - LONGi Green Energy's chairman Zhong Baoshan believes the photovoltaic industry is at a pivotal moment, emphasizing the need for technological innovation to navigate challenges and capitalize on the global green energy transition [34] Group 4 - Inspur's chairman Li Jun emphasizes the transformative impact of artificial intelligence on the global economy and the importance of open collaboration to unlock AI's potential, with a focus on building a comprehensive innovation ecosystem by 2026 [35] - TCL's chairman Li Dongsheng highlights the need for strategic focus on achieving global leadership and enhancing core capabilities to drive high-quality development amid economic uncertainties in 2026 [36] - Trina Solar's co-chairman Gao Haichun emphasizes the company's evolution from a product supplier to a system-level innovator, focusing on creating solutions that transcend traditional competition by 2026 [38] Group 5 - JinkoSolar's chairman Li Xian-de discusses the potential of space photovoltaic technology as a sustainable energy solution for future AI power needs, marking the company's 20th anniversary with a vision for universal solar energy [39] - Leo Group's chairman Wang Xiangrong aims to enhance the company's strategic focus and sustainable value, emphasizing collaboration with customers and employees to achieve higher-dimensional value creation by 2026 [40] - Innovent Biologics' chairman Cui Jisong outlines the company's commitment to innovation and global expansion, aiming to launch multiple new drugs and maintain an entrepreneurial spirit in the face of uncertainty by 2026 [41]

Group 1 - Huawei's rotating chairman Meng Wanzhou emphasized the importance of resilience and professionalism in overcoming challenges and creating value, highlighting the long-term strategic opportunities presented by the wave of intelligent transformation [25] - Hengrui Medicine's chairman Sun Piaoyang announced plans to increase R&D investment, focusing on oncology, autoimmune, and metabolic diseases, while promoting international cooperation and accelerating overseas clinical trials [26] - Wanhua Chemical's chairman Liao Zengtai aims to enhance operational quality and focus on technological innovation, particularly in battery materials and high-end new materials [27] Group 2 - Muyuan Foods' chairman Qin Yinglin expressed commitment to smart pig farming and improving animal health, aiming to enhance the quality and safety of pork for consumers [28] - Gree Electric's chairman Dong Mingzhu plans to deepen the core business while accelerating in smart equipment and renewable energy sectors, emphasizing a commitment to green and digital transformation [29] - Geely Holding Group's chairman Li Shufu highlighted the importance of making bold decisions during critical moments, focusing on core values and sustainable development [30] Group 3 - SAIC Motor's chairman Wang Xiaoqiu stated the company will deepen reforms and focus on intelligent and electric vehicle development, aiming for high-quality growth [30] - Hengli Group's chairman Chen Jianhua emphasized the need for a proactive approach to overcome challenges and achieve breakthroughs in the coming years [31] - LONGi Green Energy's chairman Zhong Baoshen believes the photovoltaic industry is at a pivotal moment, with significant opportunities for innovation and growth [32] Group 4 - TCL's chairman Li Dongsheng stressed the importance of maintaining strategic focus and enhancing core capabilities to achieve high-quality development [33] - Inspur's acting chairman Li Jun highlighted the transformative impact of artificial intelligence on the economy and the need for open and collaborative innovation [35] - Trina Solar's co-chairman Gao Haichun mentioned the company's evolution from a product supplier to a solution provider, focusing on system-level product innovation [36] Group 5 - JinkoSolar's chairman Li Xian-de discussed the potential of space photovoltaic technology as a sustainable energy solution for future challenges [37] - LEO Technology's chairman Wang Xiangrong emphasized the importance of creating value beyond mere data growth, focusing on sustainable and collaborative progress [38] - Innovent Biologics' chairman Cui Jisong outlined the company's commitment to innovation and global expansion in the next decade [39] Group 6 - Fosun International's chairman Guo Guangchang highlighted the growing demand for health and wellness, emphasizing the need to leverage the company's strengths in various industries [40] - Obsidian Technology's chairman Huang Yuanhao expressed the importance of innovation in robotics and AI vision, aiming to lead in the upcoming technological revolution [41] - Volkswagen's chairman Yang Guoping emphasized the commitment to brand and innovation as the company embarks on a new journey in the "14th Five-Year Plan" [42]

Group 1 - The company, Innovent Biologics, announced significant progress in clinical research for its novel TYK2 inhibitor soficitinib, with the completion of patient enrollment for a Phase III registration clinical trial for moderate to severe atopic dermatitis (AD) [1] - The Phase III trial for AD included 579 patients, while the Phase II trial for vitiligo enrolled 162 patients, both trials being randomized, double-blind, and placebo-controlled [1] - Soficitinib is a highly selective oral TYK2 inhibitor developed by the company, targeting various T-cell related autoimmune diseases, with a focus on dermatological conditions such as atopic dermatitis and vitiligo [1] Group 2 - According to WHO, there are approximately 230 million people globally suffering from atopic dermatitis, making it the most burdensome non-fatal skin disease, with nearly 70 million patients in China [2] - The Phase II clinical study of soficitinib for moderate to severe atopic dermatitis achieved multiple efficacy endpoints, demonstrating superior efficacy and safety compared to other treatment modalities [2] - Vitiligo affects around 70 million people globally, characterized by the destruction of skin melanocytes, requiring long-term treatment to control lesion progression and promote repigmentation [2] Group 3 - The CEO of Innovent Biologics emphasized the significant unmet clinical needs for both atopic dermatitis and vitiligo, expressing optimism about the progress of soficitinib in addressing these chronic diseases [2]

Core Viewpoint - The company announced significant progress in the clinical research of its novel TYK2 inhibitor soficitinib (ICP-332), with the completion of patient enrollment for the Phase III registration clinical trial, marking a crucial step in addressing AD disease [1] Group 1: Company Developments - The clinical trial for soficitinib has reached a major milestone with the completion of patient enrollment [1] - Soficitinib is a novel TYK2 inhibitor developed by the company [1] Group 2: Industry Context - TYK2 is a member of the Janus kinase (JAK) family and plays a critical role in the JAK-STAT signaling pathway, which is important in the mechanisms of inflammation [1]

Group 1 - The core viewpoint is that the development of innovative drugs in China is supported by both capital market opportunities and policy reforms [1] - The Hong Kong Stock Exchange and the Sci-Tech Innovation Board have provided a platform for unprofitable companies to list, facilitating the growth of innovative pharmaceuticals over the past decade [1] - Policy support has significantly improved since the reform of the drug review system in 2015, accelerating the development of innovative drugs [1] Group 2 - The return of a large number of overseas Chinese professionals has contributed to the talent pool, further stimulating the growth of the industry [1]

Core Viewpoint - The total amount of intellectual property licensing for Chinese innovative drugs to international multinational corporations (MNCs) reached $60 billion in the first half of the year, surpassing the total for the entire year of 2024, indicating a strong growth in the sector and its ability to support innovation despite previous market weaknesses [1]. Group 1: Industry Insights - The capital obtained from licensing agreements for Chinese innovative drugs has exceeded the financing from IPOs in recent years, highlighting the importance of these agreements for the development of innovative pharmaceuticals in China [1]. - Chinese innovative drugs have become a significant representation of global innovation, showcasing the country's advancements in the pharmaceutical industry [1].

Core Viewpoint - The article discusses the strategic development goals and initiatives of the company, 诺诚健华, in response to the central economic work meeting's emphasis on expanding domestic demand and optimizing supply in the context of the 2026 economic landscape [1][3]. Group 1: Company Initiatives - The company has achieved significant milestones, including a partnership with Zenas worth over $2 billion, marking a record in the field of self-immune small molecules in China [1]. - Two innovative drugs have been approved for market launch, including the first CD19 monoclonal antibody for treating diffuse large B-cell lymphoma and the first domestically developed TRK inhibitor [2]. - The company plans to launch five to six innovative drugs and develop five to ten differentiated clinical candidates by 2026, aiming to accelerate the globalization process and enhance its core competitiveness in innovative drug development [3]. Group 2: Strategic Development Goals - By 2026, the company aims to leverage "Chinese originality" and a "global vision" to embark on a new decade of growth, focusing on innovation and global market expansion [3]. - The company intends to strengthen its overseas team capabilities and achieve globalization for three to four products, enhancing its core competitiveness in innovative drug development from China to the global market [3]. - The company will maintain a passion for entrepreneurial innovation and a keen insight to drive rapid development in a challenging environment [3].

Core Insights - The article discusses the economic outlook for 2026 and the strategic development goals of companies in response to the central economic work conference's emphasis on expanding domestic demand and optimizing supply [1][2]. Company Developments - In 2025, the company will celebrate its 10th anniversary, marking a significant milestone with multiple "China's first" achievements in the biopharmaceutical sector [7]. - The company has entered into a major collaboration with Zenas worth over $2 billion, setting a record for external licensing in China's small molecule field [7]. - The company has achieved profitability two years ahead of schedule due to significant commercial developments and partnerships [7]. Product Innovations - The company has received approval for two innovative drugs: the first CD19 monoclonal antibody for treating diffuse large B-cell lymphoma (DLBCL) and the first domestically developed next-generation TRK inhibitor [7][8]. - The company is advancing multiple clinical trials for its BCL2 inhibitor Mesutoclax, which has shown significant efficacy in treating various blood cancers [8]. - The company is also progressing with its BTK inhibitor, which has entered phase III clinical trials for several indications, including systemic lupus erythematosus (SLE) and immune thrombocytopenic purpura (ITP) [8]. Strategic Goals for 2026 - The company aims to launch five to six innovative drugs and develop five to ten differentiated clinical candidates, focusing on global expansion and innovation [9][10]. - The company plans to enhance its overseas team capabilities and accelerate its globalization efforts, targeting three to four products for global markets [10]. - The company will maintain a strong entrepreneurial spirit and agility in execution to navigate uncertainties and drive rapid growth [10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 根據2023年股權激勵計劃 授予受限制股份單位 根據上市規則第17.06A條，董事會宣佈於2025年12月31日，本公司根據2023年 股權激勵計劃授予兩名承授人1,400,000份受限制股份單位，相當於本公司於本 公告日期已發行股份總數的約0.08%。 授予受限制股份單位的詳情 授予承授人受限制股份單位的詳情如下： 授出日期： 2025年12月31日 承授人及獲授受限制股份 單位的數目： 授予兩名僱員參與者1,400,000份受限制股份單位。 概無承授人須個別披露。 購買價： 每股香港股份0.178美元（約1.39港元） – 1 – 於授出日期股份的 收市價： (i) 每股香港股份12.3港元；及 (ii) 每股人民幣股份人民幣20.52元（約2 ...

格隆汇12月31日丨诺诚健华(09969.HK)发布公告，2025年12月31日，公司根据2023年股权激励计划授予 两名承授人140万份受限制股份单位，相当于公司于本公告日期已发行股份总数的约0.08%。 ...